HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 167.46% from the stock’s current price.

Other analysts have also issued reports about the company. Raymond James began coverage on Aquestive Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $7.00 price target on the stock. JMP Securities raised their target price on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. Finally, Piper Sandler began coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $8.00.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $3.37 on Tuesday. The business’s 50 day simple moving average is $4.22 and its two-hundred day simple moving average is $2.86. The firm has a market cap of $306.35 million, a P/E ratio of -24.03 and a beta of 2.87. Aquestive Therapeutics has a 52-week low of $1.25 and a 52-week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The firm had revenue of $13.21 million during the quarter, compared to the consensus estimate of $11.79 million. On average, equities analysts forecast that Aquestive Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Activity at Aquestive Therapeutics

In related news, insider Alexander Mark Schobel sold 25,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the sale, the insider now directly owns 1,040,371 shares in the company, valued at approximately $5,399,525.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AQST. Acadian Asset Management LLC increased its holdings in shares of Aquestive Therapeutics by 238.8% in the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock worth $841,000 after purchasing an additional 388,017 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Aquestive Therapeutics by 14.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock valued at $379,000 after acquiring an additional 30,898 shares during the period. Armistice Capital LLC raised its holdings in Aquestive Therapeutics by 314.5% during the third quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after acquiring an additional 3,642,000 shares during the period. Legato Capital Management LLC bought a new stake in Aquestive Therapeutics during the fourth quarter valued at about $688,000. Finally, Jump Financial LLC bought a new stake in shares of Aquestive Therapeutics in the fourth quarter worth about $60,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.